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defect (CHD), mostly of the conotruncal type, and/or 
aortic arch defect. The etiology of the cardiac pheno-
typic variability is not currently known for the major-
ity of patients. We hypothesized that rare copy number 
variants (CNVs) outside the 22q11.2 deleted region may 
modify the risk of being born with a CHD in this sen-
sitized population. Rare CNV analysis was performed 
using Affymetrix SNP Array 6.0 data from 946 22q11DS 
subjects with CHDs (n = 607) or with normal cardiac 
anatomy (n = 339). Although there was no significant 
Abstract The 22q11.2 deletion syndrome (22q11DS; 
velocardiofacial/DiGeorge syndrome; VCFS/DGS; MIM 
#192430; 188400) is the most common microdeletion 
syndrome. The phenotypic presentation of 22q11DS is 
highly variable; approximately 60–75 % of 22q11DS 
patients have been reported to have a congenital heart 
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difference in the overall burden of rare CNVs, an over-
abundance of CNVs affecting cardiac-related genes was 
detected in 22q11DS individuals with CHDs. When the 
rare CNVs were examined with regard to gene interac-
tions, specific cardiac networks, such as Wnt signaling, 
appear to be overrepresented in 22q11DS CHD cases but 
not 22q11DS controls with a normal heart. Collectively, 
these data suggest that CNVs outside the 22q11.2 region 
may contain genes that modify risk for CHDs in some 
22q11DS patients.
Introduction
The 22q11.2 deletion syndrome (22q11DS; velo-
cardio-facial syndrome; DiGeorge syndrome, VCFS/
DGS; MIM #192430; 188400) affects approximately 
1 in 2000–4000 live births and is the most common 
microdeletion syndrome (Burn and Goodship 1996; 
Robin and Shprintzen 2005). The majority of individu-
als with 22q11DS carry the typical 3 million base pair 
(3 Mb) deletion on one chromosome 22 homolog, how-
ever, smaller nested 1.5–2 Mb deletions are seen, albeit 
in <10 % of individuals (Carlson et al. 1997; Ema-
nuel 2008). The typical 3 Mb deletion and the smaller 
nested interstitial deletions are the result of non-allelic 
homologous recombination events between low copy 
repeats that punctuate the 22q11.2 region (Edelmann 
et al. 1999; Shaikh et al. 2000). The clinical features 
attributed to the hemizygous 22q11.2 deletion are 
highly variable and include congenital heart defects 
(CHDs), dysmorphic facial features, palatal anoma-
lies, immune deficiencies, hypocalcemia, a variety of 
neuropsychiatric disorders and cognitive impairment 
(McDonald-McGinn and Sullivan 2011).
Various CHDs and/or aortic arch defects have been 
reported in approximately 60–75 % of individuals with 
22q11DS (McDonald-McGinn and Sullivan 2011; Ryan 
et al. 1997). The etiology of this cardiac phenotypic var-
iability is currently unknown, but it does not appear to 
correlate with sex, race, 22q11.2 deletion size, or parent 
of origin of the deletion (Goldmuntz et al. 2009; San-
drin-Garcia et al. 2007; Swaby et al. 2011). The reduced 
penetrance of CHDs and variable expressivity within the 
22q11DS population is influenced in part by genetic fac-
tors, since 22q11DS patients with a CHD are more likely 
to have an unaffected relative with an isolated CHD 
than 22q11DS patients with normal cardiac anatomy 
(Swaby et al. 2011). These findings are not explained by 
the inheritance of the non-deleted chromosome 22, sug-
gesting that variants outside of the 22q11.2 region may 
influence the development of CHDs in these families 
(Swaby et al. 2011). Therefore, we hypothesized that 
structural variants, possibly in the form of rare CNVs, 
may increase the risk of intracardiac and/or aortic arch 
malformations in individuals already sensitized by the 
22q11.2 deletion.
Large genic CNVs that are rare in the general popula-
tion have been identified as pathogenic in a variety of 
human diseases and disorders. Rare CNVs have also been 
associated with congenital defects, such as CHDs. Recent 
non-syndromic CHD studies have identified causative rare 
CNVs at recurrent loci, such as 1q21.1 and 8p23.1 (Gless-
ner et al. 2014; Greenway et al. 2009; Silversides et al. 
2012; Soemedi et al. 2012b; Tomita-Mitchell et al. 2012). 
A common CNV, the duplication of SLC2A3, has been 
associated with an increased risk for CHDs in 22q11DS 
(Mlynarski et al. 2015). However, rare CNVs have not been 
examined in 22q11DS, and it is not currently known if rare 
CNVs are involved in the etiology of CHDs in 22q11DS.
In this manuscript, we present the first genome-wide 
analysis of rare CNVs in 22q11DS. Rare CNV analysis was 
performed on a cohort of 946 22q11DS subjects in order to 
determine whether rare CNVs, the genes they contain and 
the pathways or networks in which those genes reside, are 
potential genetic modifiers of the highly variable cardiac 
phenotype in 22q11DS.
Materials and methods
22q11DS cohort, Affymetrix genotyping and CNV 
detection
In compliance with IRB protocols (Internal Review Board, 
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07-005352_CR2 CHOP IRB) and with informed consent, 
blood or saliva samples were obtained from 22q11DS 
subjects. A detailed description of the 22q11DS cohort’s 
recruitment criteria, cardiac phenotypic information, geno-
typing procedures using Affymetrix SNP6.0 arrays, and the 
quality control metrics used in vetting the cohort has been 
reported (Mlynarski et al. 2015). Three subjects from the 
original cohort were removed based on updated clinical 
information. A total of 946 22q11DS samples, 607 cases 
with CHDs and 339 controls with normal cardiac anatomy, 
passed all quality control metrics and were included in 
our analysis of 22q11DS rare CNVs. The specific cardiac 
defects observed in these subjects and the distribution of 
22q11.2 deletion sizes in the 22q11DS cohort have been 
previously reported (Mlynarski et al. 2015).
CNV detection using PennCNV (Wang et al. 2007) and 
CNV workshop (Gai et al. 2010) was performed as was 
previously described (Mlynarski et al. 2015). Briefly, the 
PennCNV-Affymetrix tool was used to extract the signal 
intensity data from the raw. CEL files (Wang et al. 2007) 
and the log2ratios generated by PennCNV were used in 
CNV Workshop to produce CNV calls using circular binary 
segmentation (Gai et al. 2010). The BAF and LRR plots 
were subsequently visualized using Chromosome Analysis 
Suite to support CNV calls.
Rare CNV analysis
A list of autosomal CNVs detected by >10 contiguous 
probes for deletions and 20 probes for duplications was 
generated; the LogR ratio deviation for deletions is easier 
to detect than that of duplications (Wang et al. 2007), there-
fore a more stringent threshold of 20 contiguous probes was 
used for duplications in order to prevent detecting false pos-
itives. In addition, only CNVs detected by both PennCNV 
and CNV Workshop were included in the analysis, as these 
CNVs are less likely to be false positives due to variation 
in algorithms. CNV boundaries were determined by aver-
aging the breakpoint locations predicted by PennCNV and 
CNV Workshop. Any CNVs with a 50 % or greater overlap 
with centromere, telomere, immunoglobulin regions, olfac-
tory receptor genes and/or segmental duplications were 
excluded. In addition, CNVs within 10 kb of one another 
were merged and considered as possible single contigu-
ous events. We adopted a stringent definition of rare CNVs 
in which CNVs that share ≥50 % non-reciprocal overlap 
with CNVs found in ≥1.0 % of a previously published 
control population [dbVaR accession nstd100 (Coe et al. 
2014)] were categorized as common and discarded; only 
the remaining CNVs were designated as rare and included 
in this analysis. CNV detection was performed using the 
GRCh36/hg18 build and the CNV coordinates were con-
verted to the GRCh37/hg19 build using the UCSC Genome 
Browser LiftOver tool; all subsequent analyses were per-
formed using the GRCh37/hg19 build. The genomic coor-
dinates presented in figures and tables herein are based on 
the February 2009 Human Genome Build (GRCh37/hg19).
CNV validation by qPCR
Selected CNVs were validated by SYBR Green quantita-
tive PCR (qPCR) on an ABI SDS-7500 Fast Real-Time 
PCR system (Applied Biosystems, Carlsbad, CA, USA) 
as described (Mlynarski et al. 2015). Briefly, primers were 
designed to target a minimum of two amplicons within the 
deleted/duplicated region and at least one amplicon in a 
flanking region with normal copy number for each CNV. 
Each qPCR run included amplification of a previously 
reported endogenous control with known copy number 
[RPPH1, (Mlynarski et al. 2015)], and two control DNA 
samples with normal copy number.
CNV burden analysis using the CNV Map (Zarrei et al. 
2015)
CNVs detected in the 22q11DS cohort were compared to 
the comprehensive CNV map of the human genome (Zarrei 
et al. 2015). The coordinates for the inclusive CNV map 
copy number variable regions (CNVRs) and stringent CNV 
map CNVRs were obtained from Zarrei et al.’s Tables S9 
and S10 (2015). The 22q11DS deletions and duplications 
were evaluated separately in the various CNV map analy-
ses. If ≥1 bp of a 22q11DS CNV overlapped with a CNVR, 
the 22q11DS CNV was considered to be “inside” the CNV 
map. A 22q11DS CNV was categorized as “outside” of 
the CNV map only if it did not overlap with any CNVRs. 
22q11DS CNVs that were both outside of the CNV map 
and rare (frequency <1.0 %) in the published control popu-
lation [nstd100 (Coe et al. 2014)] were classified as “ultra 
rare”. The “ultra rare” CNVs were evaluated further to 
assess CNV burden in CHD cases versus controls.
The 22q11DS CNVs were first analyzed by CN type 
using the inclusive CNV map. The 22q11DS duplications 
and deletions were compared separately to the inclusive 
CNVR gains and CNVR losses, respectively [Zarrei et al. 
Table S9 “Gains (inclusive)” and “Losses (inclusive)” 
(Zarrei et al. 2015)]. Next, the 22q11DS duplications and 
deletions were compared to all variants in the inclusive 
CNV map with the CNVR gains and CNVR losses com-
bined [Zarrei et al. Table S9 “Gains + Losses (inclusive)” 
(Zarrei et al. 2015)]. Both of the analyses were subse-
quently repeated using the stringent CNV map (Zarrei et al. 
2015). The four analyses performed using the CNV maps 
will hereafter be referred to as (1) inclusive by CN type, 
(2) inclusive all CNVRs, (3) stringent by CN type and (4) 
stringent all CNVRs.
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In silico analysis of gene function
CNVs in 22q11DS subjects that passed all selection crite-
ria were annotated using the RefSeq gene set downloaded 
from the UCSC Table browser of the GRCh37/hg19 build 
(April 2015). The Mammalian Phenotype (MP) Ontol-
ogy term annotations for each RefSeq gene were retrieved 
from the Mouse Genome Informatics (MGI) database (July 
2014 available version). Gene Ontology (GO) annotations 
were obtained from the Ensembl database (July 2014 avail-
able version). The curated KEGG, BioCarta and Reactome 
gene sets were downloaded from the Molecular Signatures 
Database (MSigDB) v4.0 (July 2013 available version) 
(Subramanian et al. 2005). Previously published analyti-
cal methods were employed to expand the annotation of 
the Mammalian Phenotype ontology terms, Gene Ontology 
terms and the MSigDB gene sets (White et al. 2014). For 
each functional term (MP and GO) and MSigDB gene set, 
we directly compared the frequency of occurrence between 
cases and controls using Fisher’s exact test. Due to high 
correlations between functional terms, the Benjamini–
Hochberg false discovery rate (FDR) estimation procedure 
was then applied as previously described (Benjamini and 
Hochberg 1995). Duplication and deletion events were 
evaluated separately, and the genes contained within the 
22q11.2 deleted region were excluded from these analyses.
Cardiac gene sets
Three sets of cardiac-related genes were acquired from 
different published sources. The “Lage” list is the manu-
ally curated set of cardiac developmental genes from Lage 
et al.; there is functional evidence for each of the 254 genes 
in the “Lage” set, as targeted mutation of these cardiac 
developmental genes has been shown to cause heart pheno-
types in mouse models (Lage et al. 2010). The “MetaCore” 
list (n = 310; Supplementary appendix 1) was derived from 
four canonical maps specific for cardiac development from 
MetaCore from Thomson Reuters: (1) “Cardiac develop-
ment BMP TGF beta signaling”, (2) “Cardiac development 
FGF ErbB signaling”, (3) “Cardiac development Role of 
NADPH oxidase and ROS”, and (4) “Cardiac development 
Wnt beta catenin Notch, VEGF IP3 and integrin signal-
ing”. The “HHE” list of high heart expression genes con-
tains the top quartile of genes (n = 4171) expressed in the 
developing mouse heart at day E14.5 (Zaidi et al. 2013); 
genes were ranked by expression level, and the top 25 % 
of genes with the highest expression were included in the 
“HHE” list.
Mouse gene expression profiling of developing heart 
and pharyngeal arches (PA) at day E9.5 was performed as 
described to generate the “Heart_High” and “PA_High” 
gene lists (Racedo et al., manuscript in submission; see 
Supplementary Information). Briefly, RNA was extracted 
from micro-dissected pharyngeal arches and heart tubes 
from wild-type mouse embryos at E9.5. cDNA was gen-
erated and hybridized to Affymetrix Mouse GeneST 1.0 
expression arrays following the manufacturer’s instruc-
tions. The resulting microarray expression data were nor-
malized, and the mouse transcripts were compiled and 
converted to human gene designations for each tissue type. 
Genes were then ranked by expression level and the top 
25 % of genes with the highest expression were included 
in each list. The “Heart_High” list contains the top quartile 
of genes expressed in the developing mouse heart at E9.5 
(n = 3872; Supplementary appendix 2). The “PA_High” 
list contains the top quartile of genes expressed in the phar-
yngeal apparatus at E9.5 (n = 3873; Supplementary appen-
dix 3).
Analysis of cardiac genes in rare CNVs
For each of the cardiac-related gene sets described above, 
we determined how many individuals carried rare CNVs 
that encompassed cardiac-related genes, and also com-
puted the number of cardiac genes detected per subject. 
The 22q11DS CHD cases and controls were analyzed 
separately using the five cardiac-related gene lists. The 
genes contained within the rare deletions, rare duplica-
tions and all rare CNVs were evaluated independently 
in each analysis. The cardiac-related gene analyses were 
then repeated using the subset of genes unique to CHD 
cases or controls.
Rare CNV genes that were only observed in CHD cases, 
or only in controls, were considered to be unique. Since 
duplications and deletions are mechanistically distinct 
genetic lesions with disparate phenotypic consequences, 
genes that were impacted by different CN event types in 
CHD cases than in controls were also considered unique. 
For example, if a gene was affected by rare deletions in 
CHD cases and by rare duplications in controls (or vice 
versa), then it was labeled as a unique gene. In total, four 
iterations of the cardiac-related gene analysis were per-
formed in order to identify and evaluate cardiac genes con-
tained within rare CNVs carried by 22q11DS CHD cases 
and controls: (1) all rare CNV genes detected in 22q11DS 
CHD cases, (2) all rare CNV genes detected in 22q11DS 
controls, (3) rare CNV genes unique to 22q11DS CHD 
cases, and (4) rare CNV genes unique to 22q11DS controls.
Functional interaction network analysis of rare CNV 
cardiac genes
A single combined set of cardiac-related genes was 
constructed from the union of the five cardiac genes 
lists (“HHE”, “Heart_High”, “PA_High”, “Lage” and 
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“MetaCore”), such that the combined set contained every 
gene in each list without any duplicates (n = 5986; Sup-
plementary appendix 4). The frequency of cardiac-related 
genes in the 22q11DS cohort was assessed to determine 
how many individuals had rare CNVs that encompassed 
each specific cardiac-related gene. This was compiled into 
a list of cardiac genes observed in subjects with CHD or 
in controls and the corresponding sample count for each 
gene. The 22q11DS CHD cases and controls were ana-
lyzed separately and the resulting cardiac gene/sample 
count lists were the input files used to create the gene 
interaction networks.
Gene interaction network analysis of the 22q11DS 
cardiac-related genes was performed using the Cytoscape 
3 (Shannon et al. 2003) ReactomeFIViz App [Reactome 
Functional Interaction (Wu et al. 2014)]. The 22q11DS 
CHD cases and controls were analyzed separately using 
all cardiac-related genes in rare CNVs. The standard 
ReactomeFIViz “Gene Set/Mutation Analysis” was imple-
mented for the CHD cases and again for controls following 
the standard protocol as described in the ReactomeFIViz 
user guide documentation (Wu et al. 2014). The interac-
tion networks were generated from a “gene/sample count” 
input file using the Reactome FI Network 2014 version 
and default parameters; linker genes were not included and 
the sample cutoff was set to 1. The networks were parti-
tioned into modules based on Reactome gene pathway 
annotations with the ReactomeFIViz built-in “cluster FI 
network” tool. A pathway enrichment analysis was run for 
each individual network module using the ReactomeFIViz 
built-in “Analyze module functions” tool. Pathways and 
modules were then filtered using an FDR cutoff of 0.05 
and module size of 4. Only genes from statistically signifi-
cant pathways were included in each module, and modules 
without statistically significant pathways (FDR ≥ 0.05) 
were excluded.
The gene interaction network analyses were then 
repeated using the cardiac-related genes unique to CHD 
cases or controls. A total of four gene interaction network 
analyses were performed with the Cytoscape 3 Reactome-
FIViz App using different “gene/sample count” input files: 
(1) all cardiac-related genes in rare CNVs from 22q11DS 
CHD cases, (2) all cardiac-related genes in rare CNVs from 
22q11DS controls, (3) rare CNV cardiac-related genes 
unique to 22q11DS CHD cases, and (4) rare CNV cardiac-
related genes unique to 22q11DS controls.
Statistical analysis
The two-tailed Fisher exact test was used for the gene 
enrichment analyses. The Wilcoxon rank sum test was used 
in the CNV burden analyses. Multiple test correction was 
performed using the Benjamini–Hochberg false discovery 
rate estimation procedure as previously described (Benja-
mini and Hochberg 1995).
Results and discussion
To identify rare CNVs that might alter risk for development 
of CHDs, CNV analysis was performed using PennCNV 
and CNV workshop on Affymetrix SNP6.0 array data from 
946 22q11DS subjects, of which 607 were CHD cases with 
intracardiac defects and/or aortic arch anomalies and 339 
were controls with a normal heart. A total of 13,310 auto-
somal CNVs outside of the 22q11.2 deleted region were 
detected by both algorithms in the 946 22q11DS individu-
als. These CNVs are unlikely to be false positives as they 
were identified by two methods and passed the probe cut-
offs that were chosen based on extensive validation testing, 
during which CNVs that met these criteria had a 100 % 
validation success rate (Mlynarski et al. 2015). The previ-
ous study determined there was no significant difference in 
CNV distribution with regard to gender, size of the 22q11.2 
deletion or type of cardiac defect (Mlynarski et al. 2015). 
Therefore, this study focusses specifically on the rare 
CNVs detected in the 22q11DS cohort, and investigates 
possible associations between rare structural variants and 
CHDs in 22q11DS individuals.
A previously published control cohort of 11,256 phe-
notypically normal individuals [dbVaR accession nstd100 
(Coe et al. 2014)] was used to determine the frequency 
of the 22q11DS CNVs in the general population. Of the 
13,310 autosomal CNVs (12,095 deletions and 1215 dupli-
cations) detected outside the 22q11.2 deleted region, 7217 
CNVs (54.22 %) occurred at a frequency <1.0 % in the 
control population (Coe et al. 2014), and were categorized 
as rare. A greater number of rare deletions (n = 6489) were 
identified than rare duplications (n = 728). The disparity 
between the number of deletions and duplications may 
be due to the more stringent threshold of 20 contiguous 
probes that was used to identify duplications in order to 
prevent detection of false positives, whereas 10 contiguous 
probes were used to identify deletions. Figure 1 depicts the 
genomic distribution of rare CNVs identified in 22q11DS 
CHD cases and controls. The rare CNVs are distributed 
relatively evenly across the genome with a slight clustering 
at 1q, 3p, 4q, 7p, 8p, 9p, 16p, 16q and 19q (Fig. 1). Perhaps 
this represents a tendency for higher CNV density in cer-
tain regions of the genome more susceptible to CN varia-
tion, especially at telomeres.
Rare CNV burden
An increased burden of rare CNVs has been associated 
with a variety of diseases and disorders (Girirajan et al. 
 Hum Genet
1 3
2013; Keller et al. 2014; Wheeler et al. 2013), including 
non-syndromic CHDs (Glessner et al. 2014; Soemedi et al. 
2012b). We therefore hypothesized that 22q11DS individu-
als with CHDs, defined as cases, may carry a higher rare 
CNV burden than 22q11DS individuals with normal hearts, 
and perhaps the greater number of rare CNVs may have 
altered their risk for developing heart defects. In order to 
assess rare CNV burden in 22q11DS, the mean number and 
size of rare CNVs carried in each subject was evaluated. 
The analysis revealed that there was no significant differ-
ence in the number of rare CNVs detected (7.65 ± 3.80 vs. 
7.58 ± 3.59, p = 0.99), or the average size of rare CNVs 
(47.21 ± 71.81 vs. 45.43 ± 65.91 kb, p = 0.66), between 
subjects with CHDs including aortic arch anomalies and 
those with a normal heart (Table 1). Furthermore, there 
Fig. 1  Genomic distribution 
of 7217 rare CNVs identi-
fied in 22q11DS subjects. 
Each autosome is depicted as 
a black horizontal line. The 
CNVs identified in 22q11DS 
CHD cases are shown above 
the line and CNVs identified in 
22q11DS controls appear below. 
Deletions are shown in red and 
duplications are shown in blue
1
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Table 1  Rare CNV burden: all rare CNVs (<1.0 %)
CHD n = 607; no CHD n = 339
a Two-tailed Fisher’s exact test
b Wilcoxon rank sum
CHD No CHD p value
# of subjects with rare CNVs 604 339 0.56a
% with rare CNVs 99.51 % 100.00 %
Mean # of rare CNVs per subject 7.65 7.58 0.99b
±StdDev ±3.80 ±3.59
Mean rare CNV length (kb) per 
subject
47.21 45.43 0.66b
±StdDev (kb) ±71.81 ±65.91
# with ≥1 rare CNV ≥500 kb 60 36 0.74a
Table 2  Rare CNV burden: rare deletions (<1.0 %)
CHD n = 607; no CHD n = 339
a Two-tailed Fisher’s exact test
b Wilcoxon rank sum
CHD No CHD p value
# of subjects with rare CNVs 602 338 0.43a
% with rare CNVs 99.18 % 99.71 %
Mean # of rare CNVs per subject 6.86 6.85 0.87b
±StdDev ±3.55 ±3.37
Mean rare CNV length (kb) per subject 26.87 27.57 0.82b
±StdDev (kb) ±43.49 ±40.91
# with ≥1 rare CNV ≥500 kb 6 8 0.16a
Table 3  Rare CNV burden: rare duplications (<1.0 %)
CHD n = 607; no CHD n = 339
a Two-tailed Fisher’s exact test
b Wilcoxon rank sum
CHD No CHD p value
# of subjects with rare CNVs 305 166 0.73a
% with rare CNVs 50.25 % 48.97 %
Mean # of rare CNVs per subject 0.79 0.73 0.48b
±StdDev ±0.96 ±0.93
Mean rare CNV length (kb) per subject 108.89 93.30 0.52b
±StdDev (kb) ±219.49 ±171.56
# with ≥1 rare CNV ≥500 kb 54 28 0.81a
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was no discernible difference in the number or size of rare 
deletions (Table 2) and rare duplications (Table 3) carried 
in 22q11DS CHD cases versus controls with 22q11DS. 
Rare CNV burden was also examined using more stringent 
CNV frequency threshold of <0.1 % (Table S1; see Sup-
plementary Information). The results of the <0.1 % rare 
CNV analyses showed that CNV burden, both in terms of 
number and size, was equivalent in CHD cases and controls 
with 22q11DS.
Since there was no difference in burden at either CNV 
frequency, the recently published CNV map (Zarrei et al. 
2015) was then utilized to further assess rare CNV bur-
den in 22q11DS (Figs. S1–S4; Tables S2–S5; see Supple-
mentary Information). 22q11DS CNVs that were absent 
from the CNV map (i.e., did not overlap with known CNV 
regions in the CNV map) and rare in the published popu-
lation control cohort, were classified as “ultra rare”. These 
CNVs were of particular interest and additional analyses 
were performed to investigate whether 22q11DS indi-
viduals with CHDs carried a greater burden of “ultra rare” 
CNVs. The burden analyses revealed that there was no 
significant difference in the number or mean size of “ultra 
rare” CNVs detected in 22q11DS individuals with CHDs 
compared to those with normal heart anatomy (Tables S6–
S9). The CNV map “ultra rare” CNV findings were con-
sistent with the other various CNV burden analyses, which 
indicates that regardless of how rare CNVs are defined, the 
burden of rare CNVs is equivalent in 22q11DS CHD cases 
and controls. Although the overall rare CNV load is not 
associated with CHDs in 22q11DS, perhaps rare CNVs of 
certain loci or cardiac-specific genes may increase the risk 
of being born with a heart defect.
Previously identified rare CNVs associated 
with non‑syndromic CHDs
Recent studies have suggested that recurrent, rare CNVs 
may contribute to the pathogenesis of non-syndromic 
CHDs (Glessner et al. 2014; Greenway et al. 2009; Sil-
versides et al. 2012). The 22q11DS cohort was assessed 
for the rare CNVs reported in these non-syndromic CHD 
studies. The most commonly reported “rare” recur-
rent rearrangement in non-syndromic CHDs is a gain 
(Erdogan et al. 2008; Geng et al. 2014; Glessner et al. 
2014; Greenway et al. 2009; Lalani et al. 2013; Serra-
Juhe et al. 2012; Silversides et al. 2012; Soemedi et al. 
2012a; Tomita-Mitchell et al. 2012; Xie et al. 2014) or 
loss (Christiansen et al. 2004; Greenway et al. 2009; Soe-
medi et al. 2012a) of 1q21.1; interestingly, this 1q21.1 
CNV was not detected in any of the 22q11DS subjects. 
One 22q11DS subject with TOF carried a deletion at 
16p13.11 that encompassed MYH11 (MIM 160745) (Fig. 
S5; Table S10), a known CHD risk gene (Zhu et al. 2006). 
CNVs impacting MYH11 have been observed in several 
non-syndromic CHD studies (Lalani et al. 2013; Soe-
medi et al. 2012b; Tomita-Mitchell et al. 2012; Xie et al. 
2014). The largest nonrecurrent rare CNV identified in the 
22q11DS cohorts was a rare 5.3 Mb deletion at 18q11.2–
12.1 that overlaps a 202 kb deletion reported by Soemedi 
et al. (2012b); the heterozygous deletion included the 
gene CDH2 (MIM 114020), which is involved in Wnt-
signaling (Fig. S6; Table S10). The previously reported 
3p25 duplication (Greenway et al. 2009), which included 
the genes RAF1 (MIM 164760) and TMEM40, was 
detected in a subject with a ventricular septal defect and 
interrupted aortic arch type B (Fig. S7). A duplication 
of PTPN11 [MIM 176876] at 12q24.13 was also identi-
fied in the same 22q11DS individual (Fig. S7). This exact 
12q24.13 duplication has not been reported in the non-
syndromic CHD literature, but variants in PTPN11 have 
been associated with non-syndromic TOF (Cordell et al. 
2013; Goodship et al. 2012). Furthermore, PTPN11 muta-
tions are known to cause a spectrum of cardiac develop-
mental defects, and are observed frequently in patients 
with Noonan syndrome and LEOPARD syndrome (Lau-
riol et al. 2015; Sznajer et al. 2007).
A variety of other CNVs identified in non-syndromic 
CHD studies were observed in the 22q11DS cohort and 
validated by qPCR (Table S10); however, these CNVs 
occurred as singletons or at low frequencies and were not 
specifically associated with CHDs. For example, the pre-
viously identified duplication of LTBP1 (MIM 150390) at 
2p22.3 (Erdogan et al. 2008), a gene that is essential for 
cardiac outflow tract septation and remodeling (Todorovic 
et al. 2007), was detected in two 22q11DS individuals 
with CHDs and in three 22q11DS individuals with normal 
heart anatomy (Fig. S8; Table S10). Since none of the non-
syndromic CHD CNVs were significantly enriched in our 
CHD subjects, various in silico analyses were performed to 
investigate whether the genes contained within these CNVs 
converged upon pathways or gene networks relevant to car-
diac development.
In silico analysis of gene function
Based on our prior analysis of common CNVs (Mlynarski 
et al. 2015), it is not surprising that overall rare CNV bur-
den and non-syndromic CHD CNVs were not associated 
with CHDs in 22q11DS. As such, we hypothesized that 
22q11DS individuals with CHDs may carry a greater bur-
den of rare CNVs that specifically impact genes and path-
ways important for proper heart development. To address 
this possibility and determine the relevance of genes 
affected by rare CNVs to cardiac development, we used 
phenotype data from Mouse Genome Informatics Resource, 
Gene Ontology, and MSigDB as previously described (Gai 
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et al. 2012; Subramanian et al. 2005). The genes deleted in 
22q11DS were excluded from this analysis.
Mammalian phenotype (MP)
MP analysis was performed on the rare CNVs to investigate 
the various phenotypes associated with genes impacted by 
CNVs in 22q11DS CHD cases versus controls. The results 
from the MP analyses are listed in Tables S11–S13. None 
of the MP terms were statistically significant after FDR 
correction and only the top 25 terms are shown (Tables 
S11–S13).
Although none of the terms passed the strict significance 
cutoff, some of the most enriched MP terms in subjects with 
CHDs were cardiac related such as “decreased ventricle 
muscle contractility” (Table S11). More MP terms relevant 
to cardiac function and heart morphology were associated 
with the rare duplications detected in CHD cases (Table 
S13) than were found in the rare deletions (Table S12) or in 
MP analysis of all rare CNV events combined (Table S11). 
Included in the top 25 MP terms associated with CHDs in 
the rare duplication analysis were: “abnormal heart size”, 
“abnormal heart left ventricle morphology”, “decreased 
cardiac muscle contractility” and “enlarged heart” (Table 
S13). In addition to the cardiac-specific terms, several 
terms involved in muscle morphology and function were 
enriched in the rare duplications such as “abnormal muscle 
physiology”, “impaired muscle contractility” and “abnor-
mal muscle fiber morphology” (Table S13). These data 
suggest that 22q11DS patients with a CHD may be carry-
ing additional CNVs that affect cardiac morphology and 
muscle function, thereby altering their risk of developing a 
heart defect.
Gene ontology (GO)
GO analysis was performed on the rare CNVs in order to 
examine the annotated biological processes, cellular com-
ponents and/or molecular functions of genes impacted by 
CNVs in CHD cases versus controls. The results from the 
GO analyses are listed in Tables S14–S16. Despite sugges-
tive Fisher’s exact test p values (<0.05), none of the GO 
terms passed the strict significance cutoff and only the top 
25 terms are shown (Table S14–S16).
Several of the GO terms associated with CHDs (albeit 
not significantly) pertain to biological processes that are 
involved in or directly impact early heart development. 
The top three terms in the rare deletion GO analysis were 
“negative regulation of cell migration”, “negative regula-
tion of cellular component movement” and “negative regu-
lation of cell motility” (Table S15). These GO terms were 
also enriched in the analysis of all rare CNVs (Table S14). 
“Cell migration” was also overrepresented in individuals 
with CHDs in the rare duplication GO analysis (Table S16). 
Together the GO analyses indicate that genes involved in 
cell migration are affected by CNVs much more frequently 
in 22q11DS individuals with CHDs than in those with nor-
mal heart anatomy.
These findings are intriguing since migration of car-
diac progenitor cells during embryogenesis is a carefully 
orchestrated process that is tightly regulated and essential 
for proper heart development (Buckingham et al. 2005). 
Causal mutations in several genes related to cell migra-
tion have been previously identified in patients with non-
syndromic CHDs (Buckingham et al. 2005; Di Felice and 
Zummo 2009; Silversides et al. 2012). Therefore, the over-
abundance of genes involved in cell migration impacted by 
CNVs in 22q11DS individuals with CHDs, may have con-
tributed to their risk of being born with a CHD by altering 
cardiac progenitor cell migration during cardiogenesis.
MSigDB gene set enrichment analysis
The KEGG, BioCarta and Reactome gene network sets 
obtained from MSigDB were used to analyze the rare 
CNVs to examine the networks and pathways associated 
with genes impacted by CNVs in CHD cases versus con-
trols. The results from the MSigDB gene set analyses are 
listed in Tables S17–S19. None of the gene sets were sta-
tistically significant after FDR correction and only the top 
25 pathways are shown (Tables S17–S19). The “KEGG_
WNT_SIGNALING_PATHWAY”, which plays an essen-
tial role in cardiac development (Buikema 2014), was 
detected in the rare deletion analysis (Table S18). Another 
known cardiac pathway was identified in the rare duplica-
tion analysis: “KEGG_ARRHYTHMOGENIC_RIGHT_
VENTRICULAR_CARDIOMYOPATHY_ARVC” (Table 
S19). Several ErbB signaling pathways that are involved in 
regulating heart morphogenesis and important during car-
diogenesis (Sanchez-Soria and Camenisch 2010) were also 
detected (Tables S17–S19).
The MP, GO and MSigDB analyses determined that 
genes and pathways involved in cardiogenesis were 
enriched in the 22q11DS CHD cases but the associations 
did not meet the strict threshold for statistical significance, 
likely because the analyses were performed using all genes 
contained within rare CNVs. Therefore, we narrowed the 
focus of the investigation and examined only the rare CNV 
genes that were relevant to cardiac development.
Cardiac genes in rare CNVs
Even though the associations were not statistically significant, 
the in silico gene function analyses indicated that several path-
ways related to cardiac development were over represented 
amongst CNVs in 22q11DS subjects with CHDs. To further 
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address the hypothesis that genes involved in cardiac devel-
opment might be impacted by rare CNVs more frequently in 
22q11DS individuals with CHDs than those with normal car-
diac anatomy, five sets of cardiac-related genes were examined. 
Zaidi et al. (2013) recently demonstrated that genes involved in 
CHDs are often expressed in the developing heart; therefore, 
we investigated genes that are highly expressed at different 
stages during cardiogenesis. The “HHE” list contains genes 
highly expressed in the mid-gestational, E14.5, mouse embry-
onic heart (Zaidi et al. 2013). Many key genes are expressed 
earlier in development, so genes that are highly expressed in 
the mouse heart tube at E9.5 were also included (the “Heart_
High” list; Racedo et al., manuscript in submission). Genes 
that are responsible for cardiac outflow tract development are 
expressed in the pharyngeal apparatus and not the heart at 
mouse stage E9.5. Since most of the anomalies observed in 
22q11DS derive from defects in the remodeling of the cardiac 
outflow tract, we therefore evaluated genes expressed in the 
pharyngeal apparatus (the “PA_High” list; Racedo et al., manu-
script in submission). We also examined the curated set of car-
diac developmental genes from Lage et al. (2010), referred to 
as the “Lage” list. In addition, the MetaCore software package 
from Thomson Reuters was used to generate the vetted “Meta-
core” list of genes involved cardiogenesis.
For each gene set, we investigated how many 22q11DS 
individuals with CHDs or with normal heart anatomy had 
rare CNVs that impacted cardiac-related genes. Although 
some of the gene sets had suggestive associations, there 
was not a statistically significant difference in the num-
ber of 22q11DS CHD cases versus controls when all rare 
CNV genes were included in the analysis (Table 4). Some 
of the cardiac-related genes were detected in both 22q11DS 
individuals with CHDs and individuals with normal heart 
anatomy. Since genes found in cases and controls are less 
likely to cause or contribute to heart defects in 22q11DS, 
these genes were removed and the analyses were repeated 
using the subset of genes that were found only in CHD 
cases or in controls but not both (Table 5). The “HHE” and 
“Heart_High” gene sets were significantly overrepresented 
amongst CHD cases in the unique gene analyses (Table 5: 
all CNVs and duplications). Genes from the “Lage” list 
were also disproportionately abundant in CHD cases as 
indicated by the high odds ratios (Table 5: deletions), but 
the gene list was not large enough for a statistically signifi-
cant enrichment. Together these analyses suggest that genes 
involved in cardiac development may be affected by rare 
CNVs at a higher frequency in 22q11DS individuals with 
CHDs compared to those with normal cardiac anatomy.
Functional interaction network analysis of rare CNV 
cardiac genes
The cardiac gene set analysis revealed that cardiac-related 
genes were statistically enriched in 22q11DS CHD cases. 
However, 22q11DS individuals with normal heart anat-
omy also carried rare CNVs that affected genes involved 
in cardiac development. Since cardiac-related genes were 
observed in both CHD cases and controls, we wanted to 
examine the genes in more detail. Therefore, gene network 
analyses were performed in order to investigate the specific 
Table 4  22q11DS subjects with cardiac-related gene(s) in rare 
CNVs: all genes in CHD cases and controls
CHD n = 607; no CHD n = 339
a Two-tailed Fisher’s exact test
CNV type Gene list CHD No CHD p valuea Odds ratio
All CNVs HHE 242 136 0.945 0.990
Heart_High 188 87 0.087 1.300
PA_High 116 58 0.484 1.145
Lage 73 31 0.194 1.358
MetaCore 21 7 0.317 1.700
Deletions HHE 190 112 0.611 0.923
Heart_High 128 60 0.234 1.243
PA_High 52 28 0.904 1.041
Lage 68 29 0.220 1.349
MetaCore 9 3 0.553 1.686
Duplications HHE 75 31 0.162 1.401
Heart_High 76 32 0.167 1.373
PA_High 70 33 0.447 1.209
Lage 5 2 1.000 1.400
MetaCore 12 5 0.799 1.347
Table 5  22q11DS subjects with cardiac-related gene(s) in rare 
CNVs: only genes UNIQUE to CHD cases or controls
CHD n = 607; no CHD n = 339
a Two-tailed Fisher’s exact test
CNV type Gene list CHD No CHD p valuea Odds ratio
All CNVs HHE 102 39 0.029 1.554
Heart_High 106 40 0.024 1.582
PA_High 98 44 0.217 1.291
Lage 11 3 0.400 2.067
MetaCore 21 7 0.317 1.700
Deletions HHE 38 17 0.472 1.265
Heart_High 42 17 0.265 1.408
PA_High 39 20 0.781 1.095
Lage 6 1 0.432 3.374
MetaCore 9 3 0.553 1.686
Duplications HHE 68 23 0.029 1.733
Heart_High 69 24 0.040 1.683
PA_High 62 26 0.243 1.370
Lage 5 2 1.000 1.400
MetaCore 12 5 0.799 1.347
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pathways and biological functions of the cardiac-related 
genes found in 22q11DS CHD cases compared to 22q11DS 
controls.
Gene network analyses were performed separately for 
the 22q11DS CHD cases and controls using all cardiac-
related genes impacted by rare CNVs. The functional 
interaction networks were constructed with the Cytoscape 
3 (Shannon et al. 2003) ReactomeFIViz App (Wu et al. 
2014). The network genes were clustered into modules 
based on gene annotation using the ReactomeFIViz “Clus-
ter FI network” tool. The modules were filtered by size and 
pathway enrichment; only statistically significant mod-
ules (FDR < 0.05) that contained four or more genes were 
retained.
The results of the CHD case gene interaction network 
analysis is shown in Fig. 2. Several of the top modules 
with pathways that are significantly enriched in CHD 
cases pertain to pathways that are important for heart 
development, which may not be surprising as the inter-
action network was constructed using the cardiac-related 
genes detected in rare CNVs. However, the striking con-
trast between the CHD case and control functional inter-
action networks was unexpected. The CHD cases and 
controls were analyzed using the same FDR and size 
cutoffs; the CHD case network contained multiple mod-
ules with many significantly enriched pathways, whereas 
none of the control modules passed the cutoff criteria. As 
a result, the module size cutoff was lowered to three for 
the control network analysis. Even with the decreased 
stringency, the control network only contained two mod-
ules: nectin adhesion pathway and EGF receptor signal-
ing pathway (Fig. 3).
Some of the cardiac-related genes were affected by 
rare CNVs in both CHD cases and controls, and thus 
were unlikely to cause CHDs in 22q11DS. Therefore, 
the network analyses were repeated using the subset of 
Fig. 2  Network of all cardiac-
related genes found in 22q11DS 
CHD cases. The functional 
interaction network was con-
structed with the Cytoscape 3 
(Shannon et al. 2003) Reac-
tomeFIViz App (Wu et al. 
2014). Each node depicts a 
cardiac-related gene detected in 
the 22q11DS CHD cases. The 
size of each node represents the 
number of subjects with rare 
CNVs containing that gene. 
Genes are clustered into mod-
ules based on pathway interac-
tions, and modules are labeled 
with the most significantly 
enriched pathway it contains
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Fig. 3  Network of all cardiac-related genes found in 22q11DS con-
trols. The functional interaction network was constructed with the 
Cytoscape 3 (Shannon et al. 2003) ReactomeFIViz App (Wu et al. 
2014). Each node depicts a cardiac-related gene detected in the 
22q11DS controls. The size of each node represents the number of 
subjects with rare CNVs containing that gene. Genes are clustered 
into modules based on pathway interactions, and modules are labeled 
with the most significantly enriched pathway it contains
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unique genes found only in CHD cases or only in con-
trols but not both. The unique gene networks were 
smaller and contained fewer genes (Figs. 4, 5), but the 
results were consistent with the previous analyses. The 
interaction network of unique genes in controls still con-
tained only two modules, neither of which was directly 
relevant to heart development: nectin adhesion pathway 
and inflammation mediated by chemokine and cytokine 
signaling pathway (Fig. 5). The same pathways important 
for cardiac development were also significantly enriched 
in the case unique gene network, further demonstrating 
that the enrichment of cardiac pathways was specific to 
CHD cases.
The statistically significant enrichment of the Wnt sign-
aling and assembly of primary cilium pathways in both of 
the CHD case network analyses was particularly intriguing 
(Figs. 2, 4). The involvement of Wnt signaling pathways 
in cell specification and differentiation during early car-
diogenesis has been well established (Buikema 2014). The 
canonical Wnt/β-catenin pathway is essential for regulat-
ing proper proliferation of second heart field cells that give 
rise to the outflow tract and right ventricle (Tzahor 2007). 
Furthermore, perturbations in Wnt/β-catenin signaling have 
been shown to cause OFT defects (Tzahor 2007), such as 
those observed in patients with 22q11DS. The assembly of 
primary cilium module was an especially interesting find-
ing, because recent discoveries in mice determined that the 
cilium has a critical role in CHD pathogenesis (Li et al. 
2015) and ciliary genes have been identified in rare CNV 
studies of patients with non-syndromic CHDs (Silversides 
et al. 2012). The network analyses indicate that cilia may 
also contribute to the etiology of CHDs in 22q11DS as 
well, but further investigations will be necessary to confirm 
this finding.
Additional pathways relevant to cardiogenesis were also 
significantly enriched in the 22q11DS CHD cases. The larg-
est module contained growth factor signaling and ErbB 
Fig. 4  Network of cardiac-
related genes unique to 
22q11DS CHD cases. The 
functional interaction network 
was constructed with the 
Cytoscape 3 (Shannon et al. 
2003) ReactomeFIViz App (Wu 
et al. 2014). Each node depicts a 
cardiac-related gene detected in 
the 22q11DS CHD cases. The 
size of each node represents the 
number of subjects with rare 
CNVs containing that gene. 
Genes are clustered into mod-
ules based on pathway interac-
tions, and modules are labeled 
with the most significantly 
enriched pathway it contains
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Fig. 5  Network of cardiac-related genes unique to 22q11DS con-
trols. The functional interaction network was constructed with the 
Cytoscape 3 (Shannon et al. 2003) ReactomeFIViz App (Wu et al. 
2014). Each node depicts a cardiac-related gene detected in the 
22q11DS controls. The size of each node represents the number of 
subjects with rare CNVs containing that gene. Genes are clustered 
into modules based on pathway interactions, and modules are labeled 
with the most significantly enriched pathway it contains
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signaling pathways (Figs. 2, 4), which have essential roles 
in embryogenesis and heart development (Perrimon et al. 
2012). Signaling by the Robo receptor was also highly over-
represented in CHD cases (Figs. 2, 4). Robo receptor sign-
aling regulates cell migration (Giovannone et al. 2012); cell 
migration is an essential process in cardiogenesis and defects 
in cell migration can lead to CHDs (Buckingham et al. 
2005; Di Felice and Zummo 2009; Silversides et al. 2012). 
The other significant pathways, sumoylation and non-sense 
mediated decay, were not directly involved in heart develop-
ment but rather pertained to more basic biological processes 
important for cell function. Together the gene interaction 
network analyses revealed that pathways important during 
cardiogenesis and essential for proper heart development are 
significantly enriched in CHD cases but not in the controls.
We originally hypothesized that individuals with 
22q11DS and CHDs have rare CNVs that affect their risk 
of being born with intracardiac and/or aortic arch malfor-
mations, and undertook this study looking for genetic modi-
fiers involved in the variable 22q11DS cardiac phenotype. 
Although no particular gene or gene family shows a striking 
number of hits within rare CNVs, the fact that pathways rel-
evant to cardiogenesis seem to converge in 22q11DS CHD 
cases and not controls is thought-provoking and warrants 
further investigation. In the future, WES or WGS studies 
may shed additional light on this intriguing finding.
Web Resources
The URLs for data presented herein are as follows:
dbVAR, http://www.ncbi.nlm.nih.gov/dbvar
Gene Ontology, http://www.geneontology.org
MetaCore, http://thomsonreuters.com/en/products-ser-
vices/pharma-life-sciences/pharmaceutical-research/meta-
core.html
Mouse Genome Informatics Resource, http://www.infor-
matics.jax.org
Online Mendelian Inheritance in Man (OMIM), http://
omim.org
Primer3, http://bioinfo.ut.ee/primer3
ReactomeFIViz, http://wiki.reactome.org/index.php/
Reactome_FI_Cytoscape_Plugin_4#
UCSC genome database, http://genome.ucsc.edu
UCSC in silico PCR, http://genome.ucsc.edu/cgi-bin/
hgPcr?command=start
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